Werewolf Therapeutics, Inc. (NASDAQ:HOWL – Get Rating) saw a significant increase in short interest in April. As of April 15th, there was short interest totalling 764,400 shares, an increase of 76.5% from the March 31st total of 433,000 shares. Based on an average daily trading volume, of 297,500 shares, the short-interest ratio is currently 2.6 days. Currently, 5.8% of the shares of the stock are short sold.
Institutional investors and hedge funds have recently modified their holdings of the business. New York State Common Retirement Fund boosted its position in Werewolf Therapeutics by 13.3% during the third quarter. New York State Common Retirement Fund now owns 14,765 shares of the company’s stock valued at $253,000 after acquiring an additional 1,734 shares during the last quarter. Geode Capital Management LLC boosted its position in shares of Werewolf Therapeutics by 26.2% during the 3rd quarter. Geode Capital Management LLC now owns 136,472 shares of the company’s stock worth $2,341,000 after purchasing an additional 28,294 shares in the last quarter. Russell Investments Group Ltd. bought a new position in shares of Werewolf Therapeutics during the 3rd quarter worth about $2,159,000. Levin Capital Strategies L.P. bought a new position in shares of Werewolf Therapeutics during the 3rd quarter worth about $257,000. Finally, Citigroup Inc. boosted its position in shares of Werewolf Therapeutics by 813.5% during the 4th quarter. Citigroup Inc. now owns 7,920 shares of the company’s stock worth $94,000 after purchasing an additional 7,053 shares in the last quarter. 69.05% of the stock is currently owned by institutional investors and hedge funds.
Shares of Werewolf Therapeutics stock opened at $4.45 on Friday. Werewolf Therapeutics has a twelve month low of $3.51 and a twelve month high of $23.99. The stock has a market cap of $123.06 million and a price-to-earnings ratio of -0.05. The company’s fifty day moving average is $4.95 and its 200 day moving average is $9.80.
Separately, Zacks Investment Research upgraded shares of Werewolf Therapeutics from a “sell” rating to a “hold” rating in a research report on Monday, April 25th. One investment analyst has rated the stock with a hold rating and five have given a buy rating to the stock. According to data from MarketBeat, Werewolf Therapeutics currently has a consensus rating of “Buy” and a consensus target price of $26.20.
Werewolf Therapeutics Company Profile (Get Rating)
Werewolf Therapeutics, Inc, a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies.
- Get a free copy of the StockNews.com research report on Werewolf Therapeutics (HOWL)
- Why is Chevron Stock Falling After Strong Earnings?
- MarketBeat: Week in Review 4/25 – 4/29
- Apple’s Numbers Complete Trifecta
- Rogers Communication Stock Should Be Launching Higher
- O’Reilly Automotive Hits A Pothole
Receive News & Ratings for Werewolf Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Werewolf Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.